You guys are the ones doing all the end zone dancing. WRB even has a new moniker to pat himself on the back because no one else will.
You are pathetic WRB. Your third new minker after wrb,monkeyfuss16 and now lifewrecker. You lost money on your October puts and Noevember calls..Tota lloser!
I was not going to post here again but with all the misinformation posted by how howabout gas bag, wrb and monkeyfuss I felt I had to.
Let me explain to you why the $100,000 was raised. It was to demonstrate that their long term funding agreement with LG is intact and this could be put in the 6K. Notice the 6K does not have a "going concern" statement by the auditor and this $100,000 draw is the reason why. This is why the stock went up when the 6K was released and will hopefully go up some more so no dilution or reverse split will be needed.
This is dead money for a while but as I said in my previous post but should go up in 2016.
Sorry my mistake! 400 placebo patients to drop a point is 400 points ie 16 placebo patients who responded with improvements of 25 points.
Look at this way. To gain an additional1 point to make the data staistically meaningfull you need to subtract a 1000 points from the placebo in aggregrate. If you have 40 placebo patients reporting a 25 point improvement that is one possible source. You mean to say in the 400 placebo there were no cognitively challenged patients over 80 who were suggestible.
I am going to stop posting here because I see no value in posting but here are a few of my observations FWIW.
Dr. A sold to protect himself, every CEO does that before pivotal results come out. I dont like the mans paranoia but I do not think he is a cheat.
The BPH indication is dormantfor a while till a detailed analysis is done unless a possible flagrant error is found. It will most likely need another trial of around 100-200 patients where the placebo response is closely monitored by trained individuals; see the ACAD last trial for how they overcome exactly the same problem.
The prostate cancer indication is promising and from the CC he seems to think it will take two years and 6 million dollars which he thinks is doable. There will be no dilution , LG will provide the finnacing through the finnacing vehicle. They have already pumped over 125 million in this co.; another 6 million in the hope of recouping the money will be no issue for them.
LG will support the price over 1 dollar if neeeded. Once they anounce the prostate trial that should help.
This is dead money for a while but the SP will cross 6 dollars in 2016.
They never give a link to the conference call. I have an app on my cellphone which records all conversations.
Dr. A claimed to have received the data at the end of last week and rushed to give investors the good news so he is not accused of insider trading. He is going to look at the data now.
Good advice. I will start with an E mail.
The conference call was surreal. I intend to get to the bottom this even if I have to spend some cash. I want the topline numbers both for this and the prostate cancer trial and feel I am entitled to it.
What I have gleaned from relistening to the conference call.
1. The drug beat the placebo at all times but was significant only within the first month.
2. Average placebo response was higher than in previous trails around 6+ and drug response 7+. This was primarily of unrealistic small no. of placebo patients with improvements of over 25. If the placebo response had been like the last botox study 5-6 the drug would have succeeded.
3. Dr. A gave no topline data and what is impressive he was able to get away with it. He also was more interested in putting expectations down. Instead of stating the topline data was significant at first month and higher but not significant at other times and they would look to see why the placebo response was unrealistically higher all he talked about other products in pipeline which is complete nonsense. There is no other product.
I am willing to contribute to hiring a lawyer to get Dr. A to answer these questions. If enough people are we may be able to get some answers.
I was looking for an answer to a question you posed previously about the utility of this drug for early prostate cancer.
I refer you to the latest study I could find it was 2011 from John Hopkins of 769 men with early prostate cancer (less than Gleason grade6). In that study about 1/3 progressed over time. You can find it at the John Hopkins Site.
In the US 217000 men are diagnosed with low grade prostate cancer and 90% including 80% of those over 75 years choose a treatment instead of surveillance.
It does seem NX1207 will have a huge market at least in the US for this indication.
In the conference call he did talk about funding with a solid partner and said a financing deal was in place, presumably LG would fund a small trial if they have gone this far.
Stay calm. The data is being looked at closely before a decision is made. It is unfortunately at least going to be a few weeks/months before we know what is happening. I would not be surprised at another small trial with some tweaking. If you want to see a similar stock with a good ending look at ACAD.
I read this post of your today for the first time. Remember ACAD they had the same problem but good results in certain aspects , so they did another study just looking at those aspects and carefully trained the people recording the responses so they would get accurate results and the rest is history.
This could very well go the same way if Recordati or another big pharma offered to run another trial in exchange for US rights (for agreed upon royalties).
I see 3 possible scenarios.
One Dr. A declares bankruptcy and moves to the Carribean. SP -.02-.05
Two. Recordati buys out company for 50 millon. SP-$1. Caveat Dr. A willing to sell.
Three. Dr. A announces promising analysis and will move forward with new small trial for BPH and proceed with prostate carcinoma trial. Recordati announces will continue trial in Euorope. Caveat LG willing to bankroll. SP-?
Take your pick
The CEO has already moved his residency from Canada to the Carribean and sold shares three times last year. Some of the money as per rumours was his divorce settlement so not sure how much money he has left to settle in the Carribean. With all his faults he was committed to the drug so not sure what happens next. Typically if the results were good for some time periods (as they were here) and they can find a way to decrease the high placebo response (see ACAD) they do a small trial. In this case no one knows anything as the CEO is paranoid and never discloses any information.
He did not even present the topline results, all he said they were similar to previous results.